NCT03896269View on ClinicalTrials.gov

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory High Risk Myelodysplastic Syndrome
Interventions
DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER